Orange Book product · Generic (ANDA)
TAVABOROLE
TAVABOROLE
At a glance
Oct 13, 2020
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Oct 13, 2020
5 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
TAVABOROLE
Strength
5%
Dosage form
SOLUTION
Route
TOPICAL
TE code
Not listed
Application
ANDA 211848
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of TAVABOROLE
- 2014KERYDINBrand (NDA)
NDA 204427 · ANACOR PHARMS INC
- 2023TAVABOROLEGeneric (ANDA)
ANDA 212294 · ZYDUS LIFESCIENCES
- 2021TAVABOROLEGeneric (ANDA)
ANDA 212215 · SUN PHARMA CANADA
- 2021TAVABOROLEGeneric (ANDA)
ANDA 212224 · CIPLA
- 2021TAVABOROLEGeneric (ANDA)
ANDA 212168 · LUPIN
- 2021TAVABOROLEGeneric (ANDA)
ANDA 211963 · CHARTWELL RX
- 2020TAVABOROLEGeneric (ANDA)
ANDA 212256 · AMNEAL
- 2020TAVABOROLEGeneric (ANDA)
ANDA 212188 · ALEMBIC
- 2020TAVABOROLEGeneric (ANDA)
ANDA 211297 · ENCUBE
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
